Greenwich LifeSciences (NASDAQ:GLSI) Upgraded by Zacks Investment Research to “Hold”

Greenwich LifeSciences (NASDAQ:GLSI – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Thursday, Zacks.com reports.

According to Zacks, “Greenwich LifeSciences Inc. is a clinical stage biopharmaceutical company focuses on the development of cancer immunotherapies for breast cancer and other human epidermal growth factor. The company’s product candidate includes GP2, which is in clinical stage. Greenwich LifeSciences Inc.is based in Stafford, Texas. “

Greenwich LifeSciences stock traded up $0.10 during midday trading on Thursday, hitting $15.87. 62,397 shares of the company’s stock were exchanged, compared to its average volume of 62,968. Greenwich LifeSciences has a 12-month low of $15.52 and a 12-month high of $48.96. The firm’s 50 day simple moving average is $19.58 and its 200 day simple moving average is $25.79.

In related news, CEO Snehal Patel bought 5,500 shares of the stock in a transaction that occurred on Friday, February 11th. The stock was purchased at an average cost of $19.80 per share, for a total transaction of $108,900.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last three months, insiders bought 18,300 shares of company stock valued at $337,956. Company insiders own 68.93% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of GLSI. OLD Mission Capital LLC acquired a new stake in shares of Greenwich LifeSciences during the third quarter worth $287,000. Tibra Equities Europe Ltd bought a new position in shares of Greenwich LifeSciences during the 3rd quarter valued at about $496,000. Jane Street Group LLC lifted its stake in Greenwich LifeSciences by 25.2% during the third quarter. Jane Street Group LLC now owns 6,891 shares of the company’s stock valued at $269,000 after buying an additional 1,388 shares in the last quarter. D. E. Shaw & Co. Inc. purchased a new stake in Greenwich LifeSciences during the fourth quarter valued at about $254,000. Finally, UBS Group AG lifted its position in shares of Greenwich LifeSciences by 467.1% in the third quarter. UBS Group AG now owns 4,310 shares of the company’s stock worth $168,000 after purchasing an additional 3,550 shares in the last quarter. 6.25% of the stock is currently owned by hedge funds and other institutional investors.

About Greenwich LifeSciences (Get Rating)

Greenwich LifeSciences, Inc, a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent recurrence of breast cancer following surgery.

Read More